SCHEMBL4480913

SCHEMBL4480913

COc1cc(CCC(=O)NC2CCCC2)ccc1Oc1nc(Nc2ccc(OCCCN3CCN(C)CC3)c(F)c2)ncc1C(=O)Nc1c(C)cccc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK1 P57059 2/20 0.47
SIK2 Q9H0K1 2/20 0.47
SIK3 Q9Y2K2 2/20 0.47
AXL P30530 3/20 0.47
LCK P06239 7/20 0.45
SRC P12931 5/20 0.45
KDR P35968 5/20 0.45
MAPK14 Q16539 3/20 0.45
TNK2 Q07912 3/20 0.43
BTK Q06187 3/20 0.42
JAK3 P52333 2/20 0.42
CSF1R P07333 3/20 0.41
STK10 O94804 1/20 0.41
RET P07949 1/20 0.41
PDGFRB P09619 1/20 0.41
KIT P10721 1/20 0.41
FLT1 P17948 1/20 0.41
TIE1 P35590 1/20 0.41
FLT4 P35916 1/20 0.41
FLT3 P36888 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499613 0.96 TNK2 (0.47) SIK1SIK2SIK3AXLLCK
SCHEMBL4484671 0.92 PTK2 (0.43) SIK1SIK2SIK3AXLLCK
SCHEMBL4501597 0.91 LCK (0.46) SIK1SIK2SIK3AXLLCK
SCHEMBL4497902 0.91 AXL (0.51) SIK1SIK2SIK3AXLLCK
SCHEMBL4483801 0.91 LCK (0.49) SIK1SIK2SIK3AXLLCK
SCHEMBL4506418 0.90 LCK (0.48) SIK1SIK2SIK3AXLLCK
SCHEMBL5689342 0.90 LCK (0.46) SIK1SIK2SIK3AXLLCK
SCHEMBL4497631 0.90 LCK (0.47) SIK1SIK2SIK3AXLLCK
SCHEMBL4487916 0.89 LCK (0.49) SIK1SIK2SIK3AXLLCK
SCHEMBL4492647 0.89 SIK1 (0.45) SIK1SIK2SIK3AXLLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP claimed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 US claimed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO claimed
US-7504396-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2009-03-17 US disclosed
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 US disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209221-A1 Substituted heterocyclic compounds and methods of use ICOS, CD4, HLA-DRB1 SIK1 1588/4885SIK2 1559/4885SIK3 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.